TTBK1

TTBK1 is a brain-enriched serine/threonine/tyrosine kinase of the casein kinase 1 superfamily that acts as an upstream driver of two distinct neurodegenerative proteinopathies (PMID:16923168, PMID:25473830). It directly phosphorylates tau at Ser198, Ser199, Ser202, and Ser422 in a Mg2+/Mn2+-dependent manner, inducing dose-dependent tau aggregation in human neuronal cells (PMID:16923168); this phosphorylation decreases tau-tubulin binding and impairs tubulin polymerization, representing a loss of normal tau function alongside the gain of aggregation propensity (PMID:32255788). In parallel, TTBK1 directly phosphorylates TDP-43 and drives its relocalization from the nucleus to cytoplasmic inclusions resembling neuropathological aggregates (PMID:25473830). Genetic epistasis in C. elegans and Drosophila places TTBK1 upstream of both tau and TDP-43 toxicity, where co-expression synergistically exacerbates pathological phosphorylation, aberrant neuronal architecture, and neuron loss (PMID:29409526, PMID:28711868). Structure-guided selective inhibitors engage TTBK1 in vivo to lower tau phosphorylation at Ser422 (PMID:33944571), and inhibition in Alzheimer's disease patient-derived lymphoblasts reduces TDP-43 phosphorylation, restores nuclear TDP-43, and blocks propagation of TDP-43 pathology (PMID:37621404).

1. 2006 High

   Establishing that a then-uncharacterized brain kinase could directly modify tau answered whether TTBK1 is a bona fide tau kinase and linked it to a candidate disease mechanism.

   Evidence In vitro kinase assay with phosphopeptide mapping and overexpression in human neuronal cells; subcellular fractionation and IHC of brain tissue

   PMID:16923168

   Open questions at the time

   • Did not establish whether endogenous TTBK1 phosphorylates tau in neurons
   • Physiological substrate beyond tau not defined
   • Regulation of kinase activity unknown
2. 2014 High

   Identifying TDP-43 as a second direct substrate showed TTBK1 is not tau-specific and connected it to TDP-43 proteinopathy via nuclear-to-cytoplasmic mislocalization.

   Evidence In vitro kinase assay, overexpression with immunofluorescence in mammalian cells, and C. elegans kinome-wide screen

   PMID:25473830

   Open questions at the time

   • TDP-43 phosphosites driving relocalization not mapped
   • Whether mislocalization is direct consequence of phosphorylation versus secondary not resolved
3. 2018 High

   Whole-organism genetic epistasis tested whether TTBK1 acts upstream of tau and TDP-43 toxicity rather than merely phosphorylating them in vitro, establishing a pathway-level role.

   Evidence C. elegans and Drosophila transgenic co-expression with behavioral, locomotor, and neuronal morphology readouts plus mutagenesis

   PMID:28711868 PMID:29409526

   Open questions at the time

   • Drosophila data raise that TTBK1-tau toxicity may act through mechanisms independent of direct tau phosphorylation
   • Mammalian in vivo confirmation of epistasis not provided
4. 2020 High

   Defining the functional consequence of TTBK1-specific tau phosphorylation answered what cellular deficit it produces, showing reduced tau-tubulin binding and impaired tubulin polymerization.

   Evidence Knockdown/overexpression in heterologous cells and primary neurons, tubulin polymerization assay, and selective inhibitor in vivo

   PMID:32255788

   Open questions at the time

   • Link between loss of tau function and downstream neurodegeneration not directly demonstrated
   • Endogenous regulation of TTBK1 in neurons not addressed
5. 2021 High

   A kinase-domain co-crystal structure enabled selective inhibitor design and demonstrated in vivo target engagement, converting TTBK1 from a candidate into a druggable target.

   Evidence Co-crystal structure of the kinase domain, medicinal chemistry optimization, and in vivo pharmacology in mouse and rat models measuring phospho-tau Ser422

   PMID:33944571

   Open questions at the time

   • Structure of full-length protein or substrate-bound complex not determined
   • Mechanism of substrate recognition not defined
6. 2023 Medium

   Testing selective inhibition in patient-derived cells assessed disease relevance, showing TTBK1 inhibition reverses TDP-43 mislocalization and blocks pathology propagation in Alzheimer's disease lymphoblasts.

   Evidence Chemical inhibitor treatment of AD patient-derived immortalized lymphocytes, western blot for TDP-43 phosphorylation/localization, and conditioned-medium propagation assay

   PMID:37621404

   Open questions at the time

   • Single lab and non-neuronal cell type (lymphoblasts)
   • Mechanism of conditioned-medium propagation and the propagating species not identified

• How endogenous TTBK1 activity is regulated and what controls its substrate selection between tau and TDP-43 in neurons remains unresolved.
• Upstream regulators and activation signals of TTBK1 unknown
• Determinants of tau-versus-TDP-43 substrate choice undefined
• No direct mammalian in vivo demonstration that TTBK1 inhibition prevents neurodegeneration